Genetic Signatures Ltd reported a 54% revenue shortfall in the second half of fiscal 2026, with H2 sales of AUD 3.1 million versus analyst expectations of AUD 6.7 million. The company’s full-year revenue totaled AUD 14.8 million, a 7% decline from the prior year, while the net loss narrowed 30% to AUD 14 million.
Cash outflows from operations improved 37% to AUD 7 million, and the company closed the fiscal year with AUD 22.1 million in cash, down slightly to AUD 21.3 million by August 25, 2026. Management cited a delayed and muted flu season in Australia, which reduced testing demand by 73% compared with the prior year, as a key factor in the revenue miss.
The company’s gross profit margin remained stable at approximately 51%, but employee expenses fell 16% following an organizational restructuring completed in April 2026. The restructuring is expected to deliver annual cost savings of about AUD 5 million in fiscal 2027. Genetic Signatures also paused a customized instrumentation development program, opting instead for off-the-shelf robotics solutions to accelerate timelines and reduce costs.
Strategic adjustments included pausing further U.S. market expansion to reassess market access, though three active sites remain operational. In the Asia-Pacific and Europe, the company projects short-term revenue growth over the next 12 to 18 months, with the first new product launch planned for early 2027 and a second later in the year. The company also confirmed ongoing discussions with Microba regarding a potential corporate transaction, while denying awareness of any talks with BCAL Diagnostics.
Genetic Signatures’ shares rose 3.75% in pre-market trading on August 26, 2026, to AUD 0.083, extending a 35.6% weekly gain but remaining 68% below its year-to-date peak and well below its 52-week high of AUD 0.43. The stock trades slightly above its 52-week low of AUD 0.051, with InvestingPro’s fair value estimate at AUD 0.06.
The company’s current ratio stood at 8.99, reflecting strong liquidity despite the revenue shortfall. Management emphasized prudent cash flow management and securing operational runway as the business resets its growth strategy.
